Safety of nonsteroidal anti-inflammatory drugs in patients with cardiovascular risk


Cite item

Full Text

Abstract

The review presents current information on the role of NSAIDs in the development of cardiovascular disasters. The development of non-desirable cardiovascular effects and an increase in cardiovascular risk with the administration of NSAIDs, most experts assess in terms of the antagonistic effect on the platelet-vascular homeostasis of metabolites of COX-thromboxane A2 and prostaglandin I2 (prostacyclin). All the presented reviews confirming an increase in the risk of MI complications in the administration of NSAIDs, indicate the class-specificity of this undesirable effect, not homogeneous for different representatives of the group. Important clinical aspects of prescribing NSAIDs for patients with low and moderate cardiovascular risk are the clinical features of the patient and the individual set of risk factors for CVD. Such pharmacokinetic characteristics of NSAIDs as a short half-life, a high degree of binding to blood plasma albumins are indicative of greater safety of NSAIDs, but the final decision must be made based on the accumulated data of clinical trials and meta-analyzes.

About the authors

A V Naumov

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Department of diseases of aging. Russian clinical investigator center of gerontologies

Email: nanton78@gmail.com
д.м.н., зав. лаб. заболеваний костно-мышечной системы Российского геронтологического научно-клинического центра Moscow, Russia

O N Tkacheva

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Department of diseases of aging. Russian clinical investigator center of gerontologies

д.м.н., проф., зав. каф. болезней старения ФДПО «РНИМУ им. Н.И. Пирогова»; директор Российского геронтологического научно-клинического центра Moscow, Russia

N O Khovasova

N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Department of diseases of aging. Russian clinical investigator center of gerontologies

к.м.н., доцент каф. болезней старения ФДПО «РНИМУ им. Н.И. Пирогова»; н.с. лаб. заболеваний костно-мышечной системы Российского геронтологического научно-клинического центра Moscow, Russia

References

  1. Голубев В.Л., Данилов А.Б., Вейн А.М. Психосоциальные факторы, гендер и боль. Журнал неврологии и психиатрии им. С.С. Корсакова. 2004;104(11):70-3.
  2. Nijs J, Malfliet A, Ickmans K. Treatment of central sensitization in patients with «unexplained» chronic pain: an update Expert. Opin Pharmacother. 2014;15(12):1671-83.
  3. Smith S.R, Deshpande B.R, Collins J.E, et al. Comparative pain reduction of oral non - steroidal anti - inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962-72. doi: 10.1016/j.joca.2016.01.135
  4. Gargallo C.J, Sostres C, Lanas А. Prevention and Treatment of NSAID Gastropathy. A. Curr Treat Options Gastro. 2014;12:398. doi: 10.1007/s119 38-014-0029-4
  5. Amer M, Bead V.R, Bathon J, Blumenthal R.S, Edwards D.N. Use of nonsteroidal anti - inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiology in Review. 2010;18(4):204-12. doi: 10.1097/crd.0b013e3181ce1521
  6. Насонов Е.Л., Лабезник Л.Б., Беленков Ю.Н. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: Алмаз, 2006.
  7. Каратеев А.Е. Возможность использования НПВП у больных с ЖКТ и кардиоваскулярными факторами риска. РМЖ. 2009;17(7):495-503.
  8. Warner T.D, Mitchel J.A. Cycloxygenase; new isoforms, new inhibitors, and new lessons from clinic. FASEB J. 2004;18:790-804. doi: 10.1096/fj.03-0645rev
  9. Solomon S.D, et al. for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-80. doi: 10.1097/01.aog.0000166692.14982.d1
  10. Elliot M. Antman A.H. A Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation. 2007;115:1634-42.
  11. Lanas A, Tornero J, Zamorano J.L. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010 Aug;69(8):1453-8. doi: 10.1136/ ard.2009.123166
  12. Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti - inflammatory drugs. Expert Opin Drug Saf. 2006;5:83-94. doi: 10.1517/14740338.5.1.83
  13. Atiquzzaman M, Kopec J, Karim M.E, Wong H, Anis A. The role of nsaids in the association between osteoarthritis and cardiovascular diseases: a population - based cohort study. Ann Rheum Dis. 2018;77(Suppl):A144. [European League Against Rheumatism (EULAR) Congress 2018: Abstract OP0190].
  14. Gomez-Lumbreras A, Vives R, Giner-Soriano M, Pera H, Fradera M, Marsal J.R, Morros R. Analgesic drugs and risk of ischaemic stroke in patients with ostheoartritis: a real world data case - control study. Ann Rheum Dis. 2018;77(Suppl):A1722. [European League Against Rheumatism (EULAR) Congress 2018: Abstract AB1253].
  15. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P.M, et al. Cardiovascular safety of non - steroidal anti - inflammatory drugs: network meta - analysis. BMJ. 2011(Jan 11);342:7086. doi: 10.1136/bmj.c7086
  16. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23.
  17. Оганов Р.Г., Денисов И.Н., Симаненков В.И. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56. doi: 10.15829/1728-8800-2017-6-5-56
  18. Food and Drug Administration [Internet]. Silver Spring, MD. FDA Briefing Information for the February 10-11, 2014 Joint Meeting of the Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee.
  19. Drug Safety Update. 2013 June;6(11):A2.
  20. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost. 2009;35:150-7. doi: 10.1055/s-0029-1220323
  21. Tantry U.S, Bliden K.P, Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705-9. doi: 10.1016/j.jacc.2005.05.090
  22. Bowbrick V.A, Mikhailidis D.P, Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost. 2003;9:137-42. doi: 10.1177/107602960300900208
  23. Craft R.M, Chavez J.J, Bresee S.J, et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med. 2004;143:301-9. doi: 10.1016/j.lab.20 04.01.011
  24. Bailey L.A, Sistino J.J, Uber W.E. Is platelet function as measured by Thrombelastograph monitoring in whole blood affected by platelet inhibitors? J Extra Corpor Technol. 2005;37:43-7.
  25. de Abajo F.J, Gil M.J, Poza P.G, Bryant V, Oliva B, Timoner J, García-Rodríguez L.A. Risk of nonfatal acute myocardial infarction associated with nonsteroidal antiinflammatory drugs, non - narcotic analgesics and other drugs used in osteoarthritis: a nested case - control study. Pharmacoepidemiology and Drug Safety. 2014. doi: 10.1002/pds
  26. Lúcio S.M, Ferreira H, Lima J, Reis S. Interactions between Oxicams and Membrane Bilayers: an Explanation for Their Different COX. Medicinal Chemistry. 2006;2:447-56. doi:2174/157340606778250199
  27. Arfè A, Scotti L, Varas-Lorenzo C, et al. Non - steroidal anti - inflammatory drugs and risk of heart failure in four European countries: nested case - control study. BMJ. 2016; p. 354-4857. doi: 10.1136/bmj.i4857
  28. Berg J, Fellier H, Christoph T, Grarup J, Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999;48(7):369-79. doi: 10.1007/s000110050474
  29. Bjordal J.M, Klovning A, Ljunggren A.E, et al. Short - term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta - analysis of randomised placebo - controlled trials. Eur J Pain. 2007;11:125-38. doi: 10.1016/j.ejpain.2006.02.013
  30. Kullich W, Klein G. Influence of the nonsteroidal antiinflammatory drug lornoxicami. v. on the secretion of the endogenous opiate peptides dynorphin and β - endorphin. Aktuel Rheumatol. 1992;17(4):128-32. doi: 10.1055/s-2008-1047362
  31. Radhofer-Welte S, Rabasseda X. Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000;36(1):55-76. doi: 10.1358/dot.2000.36.1.566627
  32. Parada L, Marstein J.P, Danilov A. Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain. Pain Manag. 2016 Oct;6(5):445-54. doi: 10.2217/pmt.16.7

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies